pioglitazone has been researched along with Nephrotic Syndrome in 5 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Nephrotic Syndrome: A condition characterized by severe PROTEINURIA, greater than 3.5 g/day in an average adult. The substantial loss of protein in the urine results in complications such as HYPOPROTEINEMIA; generalized EDEMA; HYPERTENSION; and HYPERLIPIDEMIAS. Diseases associated with nephrotic syndrome generally cause chronic kidney dysfunction.
| Excerpt | Relevance | Reference |
|---|---|---|
| "While confirmatory safety and efficacy studies are needed, these findings suggest pioglitazone (a non-immunosuppressive drug) may be useful to enhance proteinuria reduction in some children and young adults with complicated NS." | 8.31 | Pioglitazone enhances proteinuria reduction in complicated pediatric nephrotic syndrome. ( Beng, HM; Hattori, M; Hidalgo, G; Hunley, TE; Miura, K; Ng, KH; Shirai, Y; Smoyer, WE; Wu, Q, 2023) |
| " We found that puromycin aminonucleoside-induced proteinuria in rats was significantly reduced by both high-dose glucocorticoids (79%) and pioglitazone (61%), but not low-dose glucocorticoids (25%)." | 7.83 | Pioglitazone Enhances the Beneficial Effects of Glucocorticoids in Experimental Nephrotic Syndrome. ( Agrawal, S; Benndorf, R; Chanley, MA; Guess, AJ; Hidalgo, G; Kitao, T; Nie, X; Smoyer, WE; Westbrook, D, 2016) |
| "Thrombosis is a potentially life-threatening nephrotic syndrome (NS) complication." | 5.56 | Nephrotic syndrome-associated hypercoagulopathy is alleviated by both pioglitazone and glucocorticoid which target two different nuclear receptors. ( Agrawal, S; Chanley, MA; Kerlin, BA; Kino, J; Smoyer, WE; Waller, AP; Wolfgang, KJ, 2020) |
| " Pioglitazone, a PPAR-γ agonist with a protective action on podocytes, was reported in a few cases as helpful in reducing proteinuria when combined with steroids." | 4.84 | Pioglitazone, a PPAR-y agonist, as one of the new therapeutic candidates for C3 glomerulopathy. ( Balestra, E; Barbi, E; Ceconi, V; Conversano, E; Di Maso, V; Pennesi, M, 2024) |
| "While confirmatory safety and efficacy studies are needed, these findings suggest pioglitazone (a non-immunosuppressive drug) may be useful to enhance proteinuria reduction in some children and young adults with complicated NS." | 4.31 | Pioglitazone enhances proteinuria reduction in complicated pediatric nephrotic syndrome. ( Beng, HM; Hattori, M; Hidalgo, G; Hunley, TE; Miura, K; Ng, KH; Shirai, Y; Smoyer, WE; Wu, Q, 2023) |
| " We found that puromycin aminonucleoside-induced proteinuria in rats was significantly reduced by both high-dose glucocorticoids (79%) and pioglitazone (61%), but not low-dose glucocorticoids (25%)." | 3.83 | Pioglitazone Enhances the Beneficial Effects of Glucocorticoids in Experimental Nephrotic Syndrome. ( Agrawal, S; Benndorf, R; Chanley, MA; Guess, AJ; Hidalgo, G; Kitao, T; Nie, X; Smoyer, WE; Westbrook, D, 2016) |
| "Acute podocyte injury and nephrotic syndrome were induced by puromycin aminonucleoside (PAN) injection in rats." | 3.78 | Protective effects of PPARγ agonist in acute nephrotic syndrome. ( Fogo, AB; Kon, V; Ma, LJ; Najafian, B; Potthoff, SA; Yang, HC; Zuo, Y, 2012) |
| "Thrombosis is a potentially life-threatening nephrotic syndrome (NS) complication." | 1.56 | Nephrotic syndrome-associated hypercoagulopathy is alleviated by both pioglitazone and glucocorticoid which target two different nuclear receptors. ( Agrawal, S; Chanley, MA; Kerlin, BA; Kino, J; Smoyer, WE; Waller, AP; Wolfgang, KJ, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 3 (60.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hunley, TE | 1 |
| Hidalgo, G | 2 |
| Ng, KH | 1 |
| Shirai, Y | 1 |
| Miura, K | 1 |
| Beng, HM | 1 |
| Wu, Q | 1 |
| Hattori, M | 1 |
| Smoyer, WE | 3 |
| Balestra, E | 1 |
| Barbi, E | 1 |
| Ceconi, V | 1 |
| Di Maso, V | 1 |
| Conversano, E | 1 |
| Pennesi, M | 1 |
| Waller, AP | 1 |
| Agrawal, S | 2 |
| Wolfgang, KJ | 1 |
| Kino, J | 1 |
| Chanley, MA | 2 |
| Kerlin, BA | 1 |
| Westbrook, D | 1 |
| Nie, X | 1 |
| Kitao, T | 1 |
| Guess, AJ | 1 |
| Benndorf, R | 1 |
| Zuo, Y | 1 |
| Yang, HC | 1 |
| Potthoff, SA | 1 |
| Najafian, B | 1 |
| Kon, V | 1 |
| Ma, LJ | 1 |
| Fogo, AB | 1 |
5 other studies available for pioglitazone and Nephrotic Syndrome
| Article | Year |
|---|---|
Pioglitazone enhances proteinuria reduction in complicated pediatric nephrotic syndrome.
Topics: Child; Glomerulosclerosis, Focal Segmental; Humans; Nephrotic Syndrome; Pioglitazone; Proteinuria; S | 2023 |
Pioglitazone, a PPAR-y agonist, as one of the new therapeutic candidates for C3 glomerulopathy.
Topics: Adolescent; Female; Humans; Immunosuppressive Agents; Mycophenolic Acid; Nephrotic Syndrome; Peroxis | 2024 |
Nephrotic syndrome-associated hypercoagulopathy is alleviated by both pioglitazone and glucocorticoid which target two different nuclear receptors.
Topics: Animals; Blood Coagulation; Child; Female; Glucocorticoids; Humans; Male; Nephrotic Syndrome; Piogli | 2020 |
Pioglitazone Enhances the Beneficial Effects of Glucocorticoids in Experimental Nephrotic Syndrome.
Topics: Albuminuria; Animals; Creatinine; Cyclooxygenase 2; Drug Therapy, Combination; Glucocorticoids; Kidn | 2016 |
Protective effects of PPARγ agonist in acute nephrotic syndrome.
Topics: Actinin; Acute Disease; Animals; Antibiotics, Antineoplastic; Aquaporin 2; Blotting, Western; Cells, | 2012 |